A team of epidemiologists, infectious disease researchers, climatologists and educators from Baylor College of Medicine, Rice University and the University of Texas School of Public Health, led by Dr. Anthony Maresso, has been awarded the inaugural Burroughs Wellcome Fund’s Climate + Health Excellence (CHEX) award, an initiative designed to strengthen research, education and public engagement related to climate change and human health.

APIC and SHEA have issued a joint statement expressing concern that the President's executive order on childhood vaccine recommendations circumvents the established scientific review process. The organizations reaffirm that vaccines are safe, effective, and essential to protecting public health.

For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10 to 15% or more. Despite their success, however, scientists have not fully understood how these drugs work in the brain. 

Now, in a new study, Yale researchers have identified an unexpected mechanism of action that challenges a long-held assumption about the brain’s hunger circuitry: that agouti-related peptide (AgRP) neurons, known as drivers of hunger, functioned solely to oppose weight loss. However, the new study shows that GLP-1 therapies like Ozempic instead recruit these neurons to help sustain fat loss. 

“This completely changes how we think about the mechanism involved in these medications and provides new insight into the biology underlying their long-term effects, opening an avenue for the development of more efficient drugs,” said Mateus d’Ávila, a Ph.D. candidate in neuroscience working in Tamas Horvath’s lab in the Department of Comparative Medicine at Yale School of Medicine (YSM) and first author of the study.